{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.508",
  "meta": {
    "versionId": "12",
    "lastUpdated": "2019-12-04T01:00:20.000-05:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.508",
  "version": "20191204",
  "name": "Flow Cytometry Studies Performed",
  "status": "active",
  "date": "2019-12-04T01:00:20-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "concept": [
          {
            "code": "1012415",
            "display": "Flow cytometry, interpretation"
          },
          {
            "code": "3170F",
            "display": "Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)"
          },
          {
            "code": "88184",
            "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker"
          },
          {
            "code": "88185",
            "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)"
          },
          {
            "code": "88187",
            "display": "Flow cytometry, interpretation; 2 to 8 markers"
          },
          {
            "code": "88189",
            "display": "Flow cytometry, interpretation; 16 or more markers"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:5ef17645-9a71-4591-952c-0e1930c743a3",
    "timestamp": "2022-06-10T07:44:18-04:00",
    "total": 6,
    "offset": 0,
    "parameter": [
      {
        "name": "count",
        "valueInteger": 1000
      },
      {
        "name": "offset",
        "valueInteger": 0
      }
    ],
    "contains": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "1012415",
        "display": "Flow cytometry, interpretation"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "3170F",
        "display": "Baseline flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "88184",
        "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "88185",
        "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "88187",
        "display": "Flow cytometry, interpretation; 2 to 8 markers"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "88189",
        "display": "Flow cytometry, interpretation; 16 or more markers"
      }
    ]
  }
}